1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine
• 英文别名: 2-azaniumylethyl [(2R)-2,3-bis[[(Z)-hexadec-9-enoyl]oxy]propyl] phosphate
• 化学式: C37H70NO8P
• 分子量: 687.9
• InChiKey: PGPMCWZMPPZJML-NAFNZUQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.6
• 重原子数：
  47
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  139
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-2,3-bis-hexadec-9c-enoyloxy-propan-1-ol 、 1-[(2R,3R,4S,5R)-5-[[[2-aminoethoxy(hydroxy)phosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]-4-iminopyrimidin-2-olate 生成 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine 、 cytidine 5'-monophosphate 、 氢(+1)阳离子
  参考文献：
  名称：

  Henneberry A.L.; McMaster C.R., Biochem J, 1999, 0264-6021, 291-8

  摘要：

  DOI：

文献信息

• [EN] BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS<br/>[FR] MOLÉCULES DE PEG RAMIFIÉ, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：PHASERX INC

  公开号：WO2018126084A1

  公开（公告）日：2018-07-05

  Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.

  揭示了分支聚乙二醇（PEG）分子，包括分支PEG-脂质和分支PEG-蛋白质，以及制备分支PEG分子的相关组合物和方法。还公开了相关的组合物、系统和方法，用于体内传递治疗和诊断试剂。
• Lipid-Conjugated Rhamnose for Immune System Recruitment and Oncotherapy
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20140112975A1

  公开（公告）日：2014-04-24

  L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions.

  L-岩藻糖抗原-脂质共轭物用于招募免疫系统到肿瘤生长部位，以启动抗肿瘤抗原反应。介绍L-岩藻糖抗原共轭脂质进入细胞膜的方法，使L-岩藻糖抗原显示在细胞表面。细胞可以是肿瘤细胞，更具体地可以是黑色素瘤细胞。将细胞与一个或多个L-岩藻糖抗原-脂质共轭物接触，使L-岩藻糖抗原-脂质共轭物插入细胞膜。例如，可以通过肿瘤内注射接触细胞。含有L-岩藻糖抗原-脂质共轭物的制药组合物和使用共轭物和组合物的治疗方法。
• CARRIER FOR NEGATIVELY CHARGED DRUGS COMPRISING A CATIONIC LIPID AND A PREPARATION METHOD THEREOF
  申请人：Choi Sung-Won

  公开号：US20130266641A1

  公开（公告）日：2013-10-10

  Disclosed are a carrier for delivering a negatively charged drug, comprising a cationic lipid represented by formula 1, and a preparation method thereof. Also disclosed is a pharmaceutical composition comprising a negatively charged drug and a cationic lipid represented by formula 1, wherein the negatively charged drug forms a complex with the cationic lipid. The composition can increase the in vivo stability of the negatively charged drug after local or systemic administration and allows the intracellular delivery of the negatively charged drug. Thus, the composition will be useful for improving the therapeutic effect of the negatively charged drug.

  本发明公开了一种用于传递负电药物的载体，包括由公式1表示的阳离子脂质以及其制备方法。还公开了一种药物组合物，包括由公式1表示的阳离子脂质和负电药物，其中负电药物与阳离子脂质形成复合物。该组合物可以增加局部或全身给药后负电药物的体内稳定性，并允许负电药物的细胞内传递。因此，该组合物对于提高负电药物的治疗效果将是有用的。
• PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG AND A PRODUCTION METHOD THEREOF
  申请人：Kim Se-Ho

  公开号：US20110268772A1

  公开（公告）日：2011-11-03

  Disclosed are an anionic drug-containing pharmaceutical composition comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The pharmaceutical composition may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs.

  揭示了一种阴离子药物含有制药组合物，包括：阴离子药物作为活性成分；阳离子脂质；和一种两亲嵌段共聚物，其中阴离子药物与阳离子脂质形成复合物，该复合物被嵌入两亲嵌段共聚物的胶束结构中，并提供了制备方法。该制药组合物可以增加阴离子药物在血液或体液中的稳定性，并可以实现细胞内输送，提高阴离子药物的功效。
• POLYMERIC MICELLE PARTICLE COMPRISING ANIONIC DRUGS AND METHOD OF PREPARING THE SAME
  申请人：SAMYANG BIOPHARMACEUTICALS CORPORATION

  公开号：US20160228361A1

  公开（公告）日：2016-08-11

  Disclosed are an anionic drug-containing polymeric micelle particle comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The particle may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs.

  本发明涉及一种阴离子药物含量的聚合物胶束粒子，包括：一种阴离子药物作为活性成分；一种阳离子脂质；以及一种两性块共聚物，其中阴离子药物与阳离子脂质形成复合物，并且该复合物被包裹在两性块共聚物的胶束结构中，以及其制备方法。该粒子可以增加阴离子药物在血液或体液中的稳定性，并且可以实现细胞内输送，以提高阴离子药物的疗效。